{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:15:34Z","timestamp":1784744134708,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jchromb.2020.122491","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T19:24:14Z","timestamp":1607714654000},"page":"122491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Development and application of an HPLC-DAD technique for human plasma concentration monitoring of perampanel and lamotrigine in drug-resistant epileptic patients"],"prefix":"10.1016","volume":"1162","author":[{"given":"Rosa","family":"Saben\u00e7a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Bicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia","family":"Carona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Sales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2020.122491_b0005","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/epi.13201","article-title":"Epilepsy priorities in Europe: a report of the ILAE-IBE epilepsy advocacy Europe task force","volume":"56","author":"Baulac","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.jchromb.2020.122491_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2017.00301","article-title":"Drug-resistant epilepsy: Multiple hypotheses, few answers","volume":"8","author":"Tang","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jchromb.2020.122491_b0015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.seizure.2011.01.004","article-title":"Combining antiepileptic drugs - rational polytherapy?","volume":"20","author":"Brodie","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.jchromb.2020.122491_b0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/epi.12494","article-title":"Medical management of refractory epilepsy - practical treatment with novel antiepileptic drugs","volume":"55","author":"Ben-Menachem","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.jchromb.2020.122491_b0025","series-title":"Chapter 43: Mechanisms of action of antiepileptic drugs","author":"Rogawski","year":"2015"},{"key":"10.1016\/j.jchromb.2020.122491_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107966","article-title":"Mechanisms of action of currently used antiseizure drugs","volume":"168","author":"Sills","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jchromb.2020.122491_b0035","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/FTD.0000000000000416","article-title":"Therapeutic drug monitoring for perampanel in japanese epilepsy patients: influence of concomitant antiepileptic drugs","volume":"39","author":"Yamamoto","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jchromb.2020.122491_b0040","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40268-016-0148-6","article-title":"An updated overview on therapeutic drug monitoring of recent antiepileptic drugs","volume":"16","author":"Jacob","year":"2016","journal-title":"Drugs R D."},{"key":"10.1016\/j.jchromb.2020.122491_b0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jchromb.2020.122491_b0050","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.jchromb.2020.122491_b0055","doi-asserted-by":"crossref","first-page":"87","DOI":"10.14581\/jer.18014","article-title":"Prolonged stupor in perampanel overdose and pharmacokinetic considerations","volume":"8","author":"Kim","year":"2018","journal-title":"J. Epilepsy Res."},{"key":"10.1016\/j.jchromb.2020.122491_b0060","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/ph3061909","article-title":"Therapeutic drug monitoring of the newer anti-epilepsy medications","volume":"3","author":"Krasowski","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jchromb.2020.122491_b0065","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.microc.2016.09.007","article-title":"Determination of lamotrigine in human plasma and saliva using microextraction by packed sorbent and high performance liquid chromatography\u2013diode array detection: An innovative bioanalytical tool for therapeutic drug monitoring","volume":"130","author":"Ventura","year":"2017","journal-title":"Microchem. J."},{"key":"10.1016\/j.jchromb.2020.122491_b0070","unstructured":"European Medicines Agency, Lamictal: summary of product characteristics, (2008) 1\u2013114."},{"key":"10.1016\/j.jchromb.2020.122491_b0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yebeh.2017.05.036","article-title":"Use of perampanel in children and adolescents with Lennox-Gastaut Syndrome","volume":"74","author":"Auvin","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.jchromb.2020.122491_b0080","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.jchromb.2020.122491_b0085","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/FTD.0000000000000350","article-title":"Development and validation of an HPLC-UV assay for the therapeutic monitoring of the new antiepileptic drug perampanel in human plasma","volume":"38","author":"Franco","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jchromb.2020.122491_b0090","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/FTD.0000000000000531","article-title":"A liquid chromatography-mass spectrometry assay for determination of perampanel and concomitant antiepileptic drugs in the plasma of patients with epilepsy compared with a fluorescent HPLC assay","volume":"40","author":"De Grazia","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jchromb.2020.122491_b0095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.plabm.2017.11.003","article-title":"Simple and rapid validated HPLC-fluorescence determination of perampanel in the plasma of patients with epilepsy","volume":"10","author":"Mohamed","year":"2018","journal-title":"Pract. Lab. Med."},{"key":"10.1016\/j.jchromb.2020.122491_b0100","unstructured":"European Medicines Agency, ICH guideline M10 on bioanalytical method validation (EMA\/CHMP\/ICH\/172948\/2019), 44 (2019) 1\u201360."},{"key":"10.1016\/j.jchromb.2020.122491_b0105","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1570-0232(02)00244-1","article-title":"Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods","volume":"774","author":"Almeida","year":"2002","journal-title":"J. Chromatogr. B Anal. Technol. Biomed Life Sci."},{"key":"10.1016\/j.jchromb.2020.122491_b0110","first-page":"1","article-title":"Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"KDIGO","year":"2013","journal-title":"Off. J. Int. Soc. Nephrol."},{"key":"10.1016\/j.jchromb.2020.122491_b0115","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4155\/bio-2017-0199","article-title":"Development and full validation of an innovative HPLC-diode array detection technique to simultaneously quantify lacosamide, levetiracetam and zonisamide in human plasma","volume":"10","author":"Gon\u00e7alves","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2020.122491_b0120","doi-asserted-by":"crossref","unstructured":"M. Dong, Basic Terms and Concepts, in: Mod. HPLC Pract. Sci., John Wiley & Sons, 2006, pp. 15\u201344.","DOI":"10.1002\/0471973106.ch2"},{"key":"10.1016\/j.jchromb.2020.122491_b0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0731-7085(97)00198-2","article-title":"Validation of bioanalytical methods","volume":"17","author":"Hartmann","year":"1998","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2020.122491_b0130","doi-asserted-by":"crossref","unstructured":"D.A. Wells, Chapter 9: Liquid-liquid extraction: strategies for method development and optimization, in: Prog. Pharm. Biomed. Anal., Elsevier, 2003, pp. 307\u2013326.","DOI":"10.1016\/S1464-3456(03)80011-X"},{"key":"10.1016\/j.jchromb.2020.122491_b0135","unstructured":"World Health Organization (WHO), Body mass index - BMI, (n.d.). https:\/\/www.euro.who.int\/en\/health-topics\/disease-prevention\/nutrition\/a-healthy-lifestyle\/body-mass-index-bmi."},{"key":"10.1016\/j.jchromb.2020.122491_b0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cca.2008.06.017","article-title":"Establishing age\/sex related serum creatinine reference intervals from hospital laboratory data based on different statistical methods","volume":"396","author":"Pottel","year":"2008","journal-title":"Clin. Chim. Acta."},{"key":"10.1016\/j.jchromb.2020.122491_b0145","unstructured":"European Medicines Agency, Fycompa: summary of product characteristics, (2012) 1\u201375."},{"key":"10.1016\/j.jchromb.2020.122491_b0150","unstructured":"Food and Drug Administration, Fycompa: highlights on prescribing information, (2012) 1\u201331."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023220313672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023220313672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:02:11Z","timestamp":1761606131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023220313672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":30,"alternative-id":["S1570023220313672"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2020.122491","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and application of an HPLC-DAD technique for human plasma concentration monitoring of perampanel and lamotrigine in drug-resistant epileptic patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2020.122491","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122491"}}